GlassScriptPhysician profile
Gangaram Rasa
NPI 1982716379
$1,223.10
in general payments reported to CMS, 2019-2025
10 companies · $204 in 2025
The $204 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.00 · 2021: $47.54 · 2022: $197 · 2023: $41.14 · 2024: $713 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $619 · Food and Beverage: $339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $618.84 |
| Food and Beverage | $339.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $728.20 | 2024-2025 | Emblem Mri S-Icd, Bodyguardian, Cds - Mct/Cem Monitoring |
| Medtronic, INC. | $174.68 | 2022-2023 | Abre |
| Abbott Laboratories | $97.01 | 2021-2025 | Esprit |
| E.R. Squibb & Sons, L.L.C. | $55.65 | 2024-2025 | Camzyos |
| Amgen INC. | $47.58 | 2025 | Repatha |
| Biotronik INC. | $44.99 | 2022-2023 | Nhancer Rx, Orsiro Mission, Recross |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.65 | 2023-2024 | Lifevest |
| Bardy Diagnostics, INC. | $20.00 | 2019 | |
| Pfizer INC. | $15.45 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $13.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gangaram Rasa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.